Registration Number
2121U010185, Article
popup.category
Текст
Title
The effectiveness of complex therapy with the inclusion of the ursodeoxycholic acid in patients with non-alcoholic fatty liver disease in combination with chronic obstructive pulmonary disease (AI translated)
popup.author
Khramtsova I. O.
Храмцова Ірина Олександрівна
Derbak M. A.
Дербак Марія Антонівна
Ganich T. M.
Ганич Тарас Михайлович
Boldizhar O. O.
Болдіжар Олександр Олександрович
Лазур Яна Василівна
Lazur Y. V.
Khramtsova I. O.
Khramtsova Iryna Oleksandrivna
Derbak M. A.
Derbak Mariya Antonivna
Ganich T. M.
Hanych Taras Mykhailovych
Boldizhar O. O.
Boldizhar Oleksandr Oleksandrovych
Lazur Yana Vasylivna
Lazur Y. V.
popup.publication
01-01-2021
popup.source_user
Ужгородський національний університет
popup.source
https://dspace.uzhnu.edu.ua/jspui/handle/lib/58982
popup.publisher
Wiadomości Lekarskie Medical Advances
Description
The aim: Was increase the effectiveness of treatment in patients with non-alcoholic fatty liver disease (NAFLD) comorbid with chronic obstructive pulmonary disease (COPD)
by using ursodeoxycholic acid (UDCA) in combination with ademethionine.
Materials and methods: Under observation was 98 patients with a diagnosis of NAFLD and COPD group II or their combination. Patients were divided into 3 groups: 1 (n =
36) – COPD + NASH – in addition to standard COPD therapy received UDCA 15 mg / kg / day – 6 months and ademethionine 1000 mg IV once a day for 10 days, followed by oral
administration of 500 mg 2 times per day – 20 days, and group 2 (n = 32) – COPD + hepatic steatosis – in addition to standard therapy – UDCA 15 mg / kg / day – 6 months.
Group 3 (n = 30) – COPD received standard therapy for COPD.
Results: UDCA with ademethionine on the background of standard COPD therapy reduces the clinical manifestations of NAFLD and normalizes liver function. The combination
of UDCA with ademethionine not only has a positive effect on the course of NAFLD, but also reduces the intensity of dyspnea, systemic inflammation, improves the external
respiration function and reduces anxiety and depression. Patients receiving UDCA + ademethionine for 6 months of follow-up had no exacerbations of COPD.
Conclusions: UDCA in combination with ademethionine in COPD courses have a positive effect on the course of NAFLD, and also reduces the intensity of dyspnea, improves the
external respiratory function and reduces the frequency of COPD hospitalization.
popup.nrat_date
2026-06-13
